Key Points

  • Fifteen percent of HIV-positive donors in the United States took ART within a few days before donating.

  • PrEP use proximate to donation was found in 0.6% of first-time male blood donors and by survey in 5% of MSM.

Abstract

Antiretroviral therapy (ART) to treat and pre-exposure prophylaxis (PrEP) to prevent HIV infection are effective tools to help end the HIV epidemic. However, their use could affect HIV transfusion-transmission risk. Three different ART/PrEP prevalence analyses in blood donors were conducted. First, blood samples from HIV-positive and a comparison group of infection-nonreactive donors were tested under blind using liquid chromatography-tandem mass spectrometry for ART. Second, blood donor samples from infection-nonreactive, 18- to 45-year-old, male, first-time blood donors in 6 US locations were tested for emtricitabine and tenofovir. Third, in men who have sex with men (MSM) participating in the 2017 Centers for Disease Control and Prevention National HIV Behavioral Surveillance (NHBS) from 5 US cities, self-reported PrEP use proximate to donation was assessed. In blind testing, no ART was detected in 300 infection-nonreactive donor samples, but in 299 HIV confirmed-infected donor samples, 46 (15.4%; 95% confidence interval [CI], 11.5% to 20.0%) had evidence of ART. Of the 1494 samples tested from first-time male donors, 9 (0.6%; 95% CI, 0.03% to 1.1%) had tenofovir and emtricitabine. In the NHBS MSM survey, 27 of 591 respondents (4.8%; 95% CI, 3.2% to 6.9%) reported donating blood in 2016 or 2017 and PrEP use within the same time frame as blood donation. Persons who are HIV positive and taking ART and persons taking PrEP to prevent HIV infection are donating blood. Both situations could lead to increased risk of HIV transfusion transmission if blood screening assays are unable to detect HIV in donations from infected donors.

REFERENCES

REFERENCES
1.
Busch
MP
.
Testing for HIV—the first three decades
.
ISBT Sci Ser
.
2015
;
10
(
suppl 1
):
317
-
323
.
2.
Delaney
KP
,
Hanson
DL
,
Masciotra
S
,
Ethridge
SF
,
Wesolowski
L
,
Owen
SM
.
Time until emergence of HIV test reactivity following infection with HIV-1: implications for interpreting test results and retesting after exposure
.
Clin Infect Dis
.
2017
;
64
(
1
):
53
-
59
.
3.
Masciotra
S
,
McDougal
JS
,
Feldman
J
,
Sprinkle
P
,
Wesolowski
L
,
Owen
SM
.
Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections
.
J Clin Virol
.
2011
;
52
(
suppl 1
):
S17
-
S22
.
4.
Busch
MP
,
Bloch
EM
,
Kleinman
S
.
Prevention of transfusion-transmitted infections
.
Blood
.
2019
;
133
(
17
):
1854
-
1864
.
5.
Bruhn
R
,
Lelie
N
,
Busch
M
,
Kleinman
S
;
International NAT Study Group
.
Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions
.
Transfusion
.
2015
;
55
(
6
):
1195
-
1205
.
6.
Kleinman
SH
,
Lelie
N
,
Busch
MP
.
Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion
.
Transfusion
.
2009
;
49
(
11
):
2454
-
2489
.
7.
Sobata
R
,
Shinohara
N
,
Matsumoto
C
, et al
.
First report of human immunodeficiency virus transmission via a blood donation that tested negative by 20-minipool nucleic acid amplification in Japan
.
Transfusion
.
2014
;
54
(
9
):
2361
-
2362
.
8.
Gosbell
IB
,
Hoad
VC
,
Styles
CE
,
Lee
J
,
Seed
CR
.
Undetectable does not equal untransmittable for HIV and blood transfusion
.
Vox Sang
.
2019
;
114
(
6
):
628
-
630
.
9.
Seed
CR
,
Yang
H
,
Lee
JF
.
Blood safety implications of donors using HIV pre-exposure prophylaxis
.
Vox Sang
.
2017
;
112
(
5
):
473
-
476
.
10.
Baeten
JM
,
Donnell
D
,
Ndase
P
, et al;
Partners PrEP Study Team
.
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
.
N Engl J Med
.
2012
;
367
(
5
):
399
-
410
.
11.
Desai
M
,
Field
N
,
Grant
R
,
McCormack
S
.
Recent advances in pre-exposure prophylaxis for HIV
.
BMJ
.
2017
;
359
:
j5011
.
12.
Grant
RM
,
Anderson
PL
,
McMahan
V
, et al;
iPrEx study team
.
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study
.
Lancet Infect Dis
.
2014
;
14
(
9
):
820
-
829
.
13.
Rodger
AJ
,
Cambiano
V
,
Bruun
T
, et al;
PARTNER Study Group
.
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
.
Lancet
.
2019
;
393
(
10189
):
2428
-
2438
.
14.
Centers for Disease Control and Prevention
. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2017 Update: A Clinical Practice Guideline.
Atlanta, GA
:
US Public Health Service
;
2018
.
15.
Sullivan
PS
,
Sanchez
TH
,
Zlotorzynska
M
, et al
.
National trends in HIV pre-exposure prophylaxis awareness, willingness and use among United States men who have sex with men recruited online, 2013 through 2017
.
J Int AIDS Soc
.
2020
;
23
(
3
):
e25461
.
16.
Eisinger
RW
,
Dieffenbach
CW
,
Fauci
AS
.
HIV viral load and transmissibility of HIV infection: Undetectable Equals Untransmittable
.
JAMA
.
2019
;
321
(
5
):
451
-
452
.
17.
de Souza
MS
,
Pinyakorn
S
,
Akapirat
S
, et al;
RV254/SEARCH010 Study Group
.
Initiation of antiretroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology
.
Clin Infect Dis
.
2016
;
63
(
4
):
555
-
561
.
18.
Colby
DJ
,
Trautmann
L
,
Pinyakorn
S
, et al;
RV411 study group
.
Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection
.
Nat Med
.
2018
;
24
(
7
):
923
-
926
.
19.
Henrich
TJ
,
Hatano
H
,
Bacon
O
, et al
.
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study
.
PLoS Med
.
2017
;
14
(
11
):
e1002417
.
20.
Donnell
D
,
Ramos
E
,
Celum
C
, et al;
Partners PrEP Study Team
.
The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion
.
AIDS
.
2017
;
31
(
14
):
2007
-
2016
.
21.
Smith
DK
,
Switzer
WM
,
Peters
P
, et al
.
A strategy for PrEP clinicians to manage ambiguous HIV test results during follow-up visits
.
Open Forum Infect Dis
.
2018
;
5
(
8
):
ofy180
.
22.
Kuebler
PJ
,
Mehrotra
ML
,
McConnell
JJ
, et al
.
Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial
.
Proc Natl Acad Sci USA
.
2015
;
112
(
27
):
8379
-
8384
.
23.
Pattacini
L
,
Baeten
JM
,
Thomas
KK
, et al;
Partners PrEP Study Team
.
Regulatory T-cell activity but not conventional HIV-specific T-cell responses are associated with protection from HIV-1 infection
.
J Acquir Immune Defic Syndr
.
2016
;
72
(
2
):
119
-
128
.
24.
Custer
B
,
Hughes
SD
.
Donor compliance research: what are you thinking?
Transfusion
.
2020
;
60
(
1
):
1
-
3
.
25.
Custer
B
,
Stramer
SL
,
Glynn
S
,
Williams
AE
,
Anderson
SA
.
Transfusion-transmissible infection monitoring system: a tool to monitor changes in blood safety
.
Transfusion
.
2016
;
56
(
6 Pt 2
):
1499
-
1502
.
26.
US Food and Drug Administration
. Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products.
White Oak, MD
:
Center for Biologics Research and Evaluation
;
2015
.
27.
US Food and Drug Administration
. Coronavirus (COVID-19) Update: FDA Provides Updated Guidance to Address the Urgent Need for Blood during the Pandemic.
White Oak, MD
:
Center for Biologics Research and Evaluation
;
2020
.
28.
Siegler
AJ
,
Bratcher
A
,
Weiss
KM
.
Geographic access to preexposure prophylaxis clinics among men who have sex with men in the United States
.
Am J Public Health
.
2019
;
109
(
9
):
1216
-
1223
.
29.
AIDSVU
.
ZIP Code, Community Area/Ward, Census Tract; 2018
. https://aidsvu.org/data-methods/data-methods-zip-code-census-tract/
. Accessed 25 July 2018
.
30.
MacKellar
DA
,
Gallagher
KM
,
Finlayson
T
,
Sanchez
T
,
Lansky
A
,
Sullivan
PS
.
Surveillance of HIV risk and prevention behaviors of men who have sex with men–a national application of venue-based, time-space sampling
.
Public Health Rep
.
2007
;
122
(
suppl 1
):
39
-
47
.
31.
Hoots
BE
,
Finlayson
T
,
Nerlander
L
,
Paz-Bailey
G
;
National HIV Behavioral Surveillance Study Group
.
Willingness to take, use of, and indications for pre-exposure prophylaxis among men who have sex with men—20 US cities, 2014
.
Clin Infect Dis
.
2016
;
63
(
5
):
672
-
677
.
32.
Wejnert
C
,
Hess
KL
,
Rose
CE
,
Balaji
A
,
Smith
JC
,
Paz-Bailey
G
;
NHBS Study Group
.
Age-specific race and ethnicity disparities in HIV infection and awareness among men who have sex with men—20 US Cities, 2008-2014
.
J Infect Dis
.
2016
;
213
(
5
):
776
-
783
.
33.
Parikh
UM
,
Mellors
JW
.
Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Curr Opin HIV AIDS
.
2016
;
11
(
1
):
49
-
55
.
34.
Ruone
S
,
Paxton
L
,
McLaurin
T
, et al
.
Brief Report: HIV-1 evolution in breakthrough infections in a human trial of oral pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil fumarate
.
J Acquir Immune Defic Syndr
.
2016
;
72
(
2
):
129
-
132
.
35.
Weis
JF
,
Baeten
JM
,
McCoy
CO
, et al;
Partners PrEP Study Team
.
Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation
.
AIDS
.
2016
;
30
(
1
):
31
-
35
.
36.
Riddell
J
IV
,
Amico
KR
,
Mayer
KH
.
HIV preexposure prophylaxis: a review
.
JAMA
.
2018
;
319
(
12
):
1261
-
1268
.
37.
Khalili
J
,
Landovitz
RJ
.
HIV preexposure prophylaxis: the role of primary care clinicians in ending the HIV epidemic
.
JAMA Intern Med
.
2019
;
38.
Pereyra
F
,
Addo
MM
,
Kaufmann
DE
, et al
.
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy
.
J Infect Dis
.
2008
;
197
(
4
):
563
-
571
.
39.
Eshleman
SH
,
Laeyendecker
O
,
Kammers
K
, et al
.
Comprehensive profiling of HIV antibody evolution
.
Cell Rep
.
2019
;
27
(5):
1422
-
1433.e1424
.
40.
Manak
MM
,
Jagodzinski
LL
,
Shutt
A
, et al;
RV254/SEARCH010 and the RV217 Study Teams
.
Decreased seroreactivity in individuals initiating antiretroviral therapy during acute HIV infection
.
J Clin Microbiol
.
2019
;
57
(
10
):
e00757
-
19
.
41.
Sykes
W
,
Van den Berg
K
,
Jacobs
G
, et al;
NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)
.
Discovery of “false elite controllers”: HIV antibody-positive RNA-negative blood donors found to be on antiretroviral treatment
.
J Infect Dis
.
2019
;
220
(
4
):
643
-
647
.
42.
US Food and Drug Administration
. Important Information for Potential Donors of Blood and Blood Products: Individuals Who Have Ever Tested Positive for HIV Should Not Donate Blood.
White Oak, MD
:
Center for Biologics Research and Evaluation
;
2019
.
43.
Willson
S
,
Miller
K
,
Seem
D
,
Kuehnert
MJ
.
Cognitive evaluation of the AABB Uniform Donor History Questionnaire
.
Transfusion
.
2016
;
56
(
6 Pt 2
):
1662
-
1667
.
44.
Gandhi
M
,
Gandhi
RT
,
Stefanescu
A
, et al;
A5321 Team
.
Cumulative antiretroviral exposure measured in hair is not associated with measures of HIV persistence or inflammation among individuals on suppressive ART
.
J Infect Dis
.
2018
;
218
(
2
):
234
-
238
.
45.
Saberi
P
,
Ming
K
,
Legnitto
D
,
Neilands
TB
,
Gandhi
M
,
Johnson
MO
.
Feasibility and acceptability of novel methods to estimate antiretroviral adherence: a longitudinal study
.
PLoS One
.
2019
;
14
(
1
):
e0210791
.
46.
Grebe
E
,
Busch
MP
,
Notari
EP
, et al
.
HIV incidence in US first-time blood donors and transfusion risk with a 12-month deferral for men who have sex with men
.
Blood
.
2020
;
136(11):1359-1367
.
You do not currently have access to this content.